Patents by Inventor Guangxia Gao

Guangxia Gao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-IFNAR1 ANTIBODIES
    Publication number: 20220144957
    Abstract: Provided are anti-IFNAR1 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 12, 2022
    Inventors: Jingyun LI, Wei YE, Tao LIU, Xuyuan ZHANG, Liguo ZHANG, Guangxia GAO
  • Recombinant murine leukemia virus reverse transcriptases, the genes encoding and the method for expressing it
    Patent number: 7794996
    Abstract: This invention provides recombinant murine leukemia virus reverse transcriptases, genes encoding these proteins and expression methods. The said murine leukemia virus reverse transcriptases are a series of MLV-RT proteins wherein the 84th amino acid residue (Q84) from the N-terminus is replaced with amino acid X, which is an amino acid with a side chain shorter than glutamine. The said murine leukemia virus reverse transcriptases have higher enzyme activity and processivity than the wild type enzyme, and are expected to be widely used in the field of biotechnology for cDNA synthesis.
    Type: Grant
    Filed: January 13, 2004
    Date of Patent: September 14, 2010
    Assignee: The Institute of Biophysics, Chinese Academy of Sciences
    Inventors: Guangxia Gao, Shufeng Liu
  • Recombinant Murine Leukemia Virus Reverse Transcriptases, The Genes Encoding And The Method For Expressing It
    Publication number: 20080131950
    Abstract: This invention provides recombinant murine leukemia virus reverse transcriptases, genes encoding these proteins and expression methods. The said murine leukemia virus reverse transcriptases are a series of MLV-RT proteins wherein the 84th amino acid residue (Q84) from the N-terminus is replaced with amino acid X, which is an amino acid with a side chain shorter than glutamine. The said murine leukemia virus reverse transcriptases have higher enzyme activity and processivity than the wild type enzyme, and are expected to be widely used in the field of biotechnology for cDNA synthesis.
    Type: Application
    Filed: January 13, 2004
    Publication date: June 5, 2008
    Inventors: Guangxia Gao, Shufeng Liu
  • Reverse transcriptase of moloney murine leukemia virus with RNA polymerase activity
    Patent number: 6136582
    Abstract: This invention provides a polypeptide capable of polymerizing i) deoxyribonucleotides; ii) ribonucleotides; or iii) one or more deoxyribonucleotides and one or more ribonucleotides. This invention further provides a purified Moloney murine leukemia virus reverse transcriptase, wherein an amino acid corresponding to position 155 of a wild type Moloney murine leukemia virus reverse transcriptase is a valine. This invention also provides a method of polymerizing a nucleic acid molecule comprising one or more deoxyribonucleotides and one or more ribonucleotides comprising: contacting a polypeptide capable of polymerizing i) deoxyribonucleotides; ii) ribonucleotides; or iii) one or more deoxyribonucleotides and one or more ribonucleotides with deoxyribonucleotides and ribonucleotides under conditions permitting incorporation of deoxyribonucleotides and ribonucleotides into a nucleic acid molecule.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: October 24, 2000
    Assignee: The Trustees of Columbia University in the City
    Inventors: Guangxia Gao, Stephen P. Goff